Product Description
Mechanisms of Action: TOP1 Inhibitor,TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Spectrum
Company Location: HENDERSON NV 89052
Company CEO: Thomas J. Riga
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Lymphocytic Chronic B-Cell Leukemia|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Mantle-Cell Lymphoma|Chronic Lymphoid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ELSA 2004-001 | P2 |
Completed |
Lymphocytic Chronic B-Cell Leukemia|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Mantle-Cell Lymphoma|Chronic Lymphoid Leukemia |
None |